Cardiovascular Disease study: Olpasiran
Official title Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
ClinicalTrials.gov ID: NCT07293260
What this study is testing
What is Olpasiran?
Olpasiran is an investigational once‑daily injectable medicine being studied for cardiovascular disease.
Also referred to as AMG 890.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to find out whether olpasiran lowers the amount of non‑calcified plaque in the heart, measured by a special CT scan called CCTA.
- Who it's for
- It is looking for adults who have cardiovascular disease.
- What's involved
- Participants will receive either olpasiran or a placebo and will have CT scans of their heart to measure plaque.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 80
You may be able to join if
- Age 35 to ≤ 80 years.
- Lp(a) ≥ 200 nmol/L during screening.
- Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
- History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary...
You likely can't join if
- History of coronary artery bypass graft (CABG).
- Moderate to severe renal dysfunction.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during...
- History of hemorrhagic stroke.
- History of major bleeding disorder.
- Planned cardiac surgery or arterial revascularization.
See the full eligibility criteria
- Age 35 to ≤ 80 years.
- Lp(a) ≥ 200 nmol/L during screening.
- Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
- History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary intervention.
- History of coronary artery bypass graft (CABG).
- Moderate to severe renal dysfunction.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening.
- History of hemorrhagic stroke.
- History of major bleeding disorder.
- Planned cardiac surgery or arterial revascularization.
- Severe heart failure.
- Current, recent, or planned lipoprotein apheresis.
- Previously received ribonucleic acid therapy specifically targeting Lp(a).
The study team makes the final eligibility decision.
Where it is enrolling
- Bridgeport, Connecticut, United States
- Jacksonville, Florida, United States
- Overland Park, Kansas, United States
- Bowie, Maryland, United States
- Philadelphia, Pennsylvania, United States
- Humble, Texas, United States
- Auchenflower, Queensland, Australia
- Sippy Downs, Queensland, Australia
- Leabrook, South Australia, Australia
- Vaughan, Ontario, Canada
- Beijing, Beijing Municipality, China
- Zhengzhou, Henan, China
- Changsha, Hunan, China
- Nanjing, Jiangsu, China
- Yinchuan, Ningxia, China
- Xi'an, Shaanxi, China
- Jinan, Shandong, China
- Herning, Denmark
- Viborg, Denmark
- Nice, France
+ 19 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Bridgeport, Connecticut, United States; Jacksonville, Florida, United States; Overland Park, Kansas, United States; Bowie, Maryland, United States; Philadelphia, Pennsylvania, United States; Humble, Texas, United States and 33 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.